Twin Tree Management LP Purchases Shares of 2,097 Quest Diagnostics Incorporated $DGX

Twin Tree Management LP purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,097 shares of the medical research company’s stock, valued at approximately $444,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Key Financial Inc raised its position in Quest Diagnostics by 1,728.6% during the first quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 121 shares in the last quarter. Quattro Advisors LLC purchased a new stake in Quest Diagnostics in the 4th quarter worth approximately $25,000. DV Equities LLC acquired a new stake in shares of Quest Diagnostics during the 4th quarter worth approximately $27,000. Sittner & Nelson LLC acquired a new stake in shares of Quest Diagnostics during the 4th quarter worth approximately $29,000. Finally, McIlrath & Eck LLC purchased a new position in shares of Quest Diagnostics during the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Price Performance

Shares of NYSE DGX opened at $244.34 on Monday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59. The firm has a fifty day moving average of $219.35 and a 200 day moving average of $205.29. The firm has a market cap of $26.97 billion, a PE ratio of 25.94, a PEG ratio of 2.25 and a beta of 0.56. Quest Diagnostics Incorporated has a one year low of $171.18 and a one year high of $245.68.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.30. The business had revenue of $3.04 billion for the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, research analysts predict that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.4%. Quest Diagnostics’s dividend payout ratio is presently 36.52%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on DGX shares. Wall Street Zen upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 28th. UBS Group lifted their price objective on shares of Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Jefferies Financial Group reiterated a “buy” rating and issued a $245.00 price objective on shares of Quest Diagnostics in a research report on Thursday, July 23rd. JPMorgan Chase & Co. raised their target price on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research report on Tuesday, July 28th. Finally, Mizuho lifted their price target on Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $235.31.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Mark E. Delaney sold 1,600 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the transaction, the senior vice president owned 10,335 shares in the company, valued at $2,430,585.30. This trade represents a 13.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the sale, the chief executive officer directly owned 132,423 shares in the company, valued at $25,708,601.22. This represents a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 19,747 shares of company stock valued at $3,947,088 over the last quarter. 0.88% of the stock is currently owned by insiders.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.